Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis
- PMID: 2899143
- DOI: 10.1111/j.2042-7158.1988.tb05210.x
Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis
Abstract
Suppression of Leishmania donovani liver amastigotes by sodium stibogluconate has been determined in a murine model of experimental visceral leishmaniasis. Niosomal and liposomal drug formulations were equiactive and both increased drug efficacy by an order of magnitude compared with that of free drug. Niosomes containing 30 mol % cholesterol were prepared from three different non-ionic surfactants and no significant difference in activity was detected among the different drug-loaded niosomes. Both negatively charged and neutral vesicles were found to be equally effective. However, vesicle cholesterol content had a slight influence on the antiparasitic activity of the drug-loaded niosomes. Empty vesicles produced a dose-dependent parasite suppression for all vesicles studied. Studies of antimony distribution in the mouse using neutron activation analysis showed high liver levels after i.v. administration of the carrier forms of the drug.
Similar articles
-
Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate.J Pharm Pharmacol. 1986 Jul;38(7):502-5. doi: 10.1111/j.2042-7158.1986.tb04623.x. J Pharm Pharmacol. 1986. PMID: 2875149
-
Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate.J Pharm Pharmacol. 1987 Oct;39(10):832-5. doi: 10.1111/j.2042-7158.1987.tb05126.x. J Pharm Pharmacol. 1987. PMID: 2891821
-
Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice.J Pharm Pharmacol. 1989 Feb;41(2):87-91. doi: 10.1111/j.2042-7158.1989.tb06399.x. J Pharm Pharmacol. 1989. PMID: 2568434
-
Liposomal dosage form development--some practical considerations.J Parenter Sci Technol. 1983 May-Jun;37(3):72-5. J Parenter Sci Technol. 1983. PMID: 6308198 Review. No abstract available.
-
[Treatment of visceral leishmaniasis in children].Med Trop (Mars). 2007 Feb;67(1):73-8. Med Trop (Mars). 2007. PMID: 17506279 Review. French.
Cited by
-
Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.Antimicrob Agents Chemother. 2004 Sep;48(9):3591-3. doi: 10.1128/AAC.48.9.3591-3593.2004. Antimicrob Agents Chemother. 2004. PMID: 15328135 Free PMC article.
-
Enhancement of Biological and Pharmacological Properties of an Encapsulated Polyphenol: Curcumin.Molecules. 2021 Jul 13;26(14):4244. doi: 10.3390/molecules26144244. Molecules. 2021. PMID: 34299519 Free PMC article. Review.
-
Development, physicochemical characterization, and antimicrobial evaluation of niosome-loaded oregano essential oil against fish-borne pathogens.Heliyon. 2024 Feb 19;10(5):e26486. doi: 10.1016/j.heliyon.2024.e26486. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463865 Free PMC article.
-
Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.ACS Biomater Sci Eng. 2021 May 10;7(5):1725-1741. doi: 10.1021/acsbiomaterials.0c01132. Epub 2020 Oct 14. ACS Biomater Sci Eng. 2021. PMID: 33966377 Free PMC article. Review.
-
New sterically stabilized vesicles based on nonionic surfactant, cholesterol, and poly(ethylene glycol)-cholesterol conjugates.Biophys J. 1998 Jun;74(6):3198-210. doi: 10.1016/S0006-3495(98)78026-9. Biophys J. 1998. PMID: 9635773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources